Publications by authors named "Ka Lung Wu"

20Publications

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

Lancet Haematol 2020 Jun 30;7(6):e456-e468. Epub 2020 Apr 30.

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(20)30099-5DOI Listing
June 2020

Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.

Leuk Lymphoma 2017 08 31;58(8):1872-1879. Epub 2017 Jan 31.

i Division of Medicine-Cell Therapy and Hematologica , Duke University Medical Center , Durham , NC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1263842DOI Listing
August 2017

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

N Engl J Med 2015 Aug 2;373(7):621-31. Epub 2015 Jun 2.

From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.L.); National and Kapodistrian University of Athens, Athens (M.D.); A.O.U. San Giovanni Battista di Torino-Ospedale Molinette, Turin, Italy (A.P.); QEII Health Science Center and Dalhousie University, Halifax, NS (D.W.), Cross Cancer Institute and University of Alberta, Edmonton (A.B.), and Princess Margaret Cancer Centre, Toronto (D.R.) - all in Canada; Silesian Medical University, Katowice (S.G.), and Medical University of Lublin, Lublin (A.W.-C.) - both in Poland; Charles University Hospital, Prague, Czech Republic (I.S.); University Hospital, Nantes, France (P.M.); Complejo Asistencial Universitario de Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Ramat Aviv - both in Israel (H.M.); Ankara University, Ankara, Turkey (M.B.); Alfred Health-Monash University, Melbourne, VIC, Australia (A. Spencer); Barts and the London NHS Trust, London (H.O.); University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); Kyoto Prefectural University of Medicine, Kyoto (M.T.), and Nishigunma National Hospital, Shibukawa (M.M.) - both in Japan; Universitätsklinikum der Technische Universität, Dresden (C.R.), and Universitätsklinikum Würzburg, Würzburg (H.E.) - both in Germany; Zeikenhuis Netwerk Antwerpen (ZNA) Stuivenberg, Antwerp, Belgium (K.L.W.); AbbVie Biotherapeutics, Redwood City, CA (A. Singhal); Bristol-Myers Squibb, Princeton, NJ (J.K.), Wallingford, CT (E.B.), and Braine-l'Alleud, Belgium (V.P.); and Dana-Farber Cancer Institute, Boston (K.C.A., P.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1505654DOI Listing
August 2015

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.

Cancer Chemother Pharmacol 2014 Jan 23;73(1):35-42. Epub 2013 Oct 23.

Division of Cancer Medicine, Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0429, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2314-7DOI Listing
January 2014

Massilia timonae infection presenting as generalized lymphadenopathy in a man returning to Belgium from Nigeria.

J Clin Microbiol 2011 Jul 27;49(7):2763-5. Epub 2011 Apr 27.

Department of Hematology, ZNA Stuivenberg, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/JCM.00160-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147811PMC
July 2011

Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.

Clin Lymphoma Myeloma 2007 Jan;7(4):280-5

Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLM.2007.n.003DOI Listing
January 2007

Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.

J Am Acad Dermatol 2006 Nov 22;55(5):897-900. Epub 2006 Aug 22.

Department of Hematology, Erasmus MC, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S019096220601833
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2006.06.030DOI Listing
November 2006

Diagnosis of neurolymphomatosis with FDG PET.

Neurology 2006 Aug;67(4):722-3

Departments of Neurology/Neuro-Oncology, Daniel den Hoed Cancer Center/Erasmus University Hospital, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000230155.67464.37DOI Listing
August 2006

Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.

Clin Lymphoma Myeloma 2005 Sep;6(2):96-101

Department of Hematology, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155791901170376
Publisher Site
http://dx.doi.org/10.3816/CLM.2005.n.035DOI Listing
September 2005